6 ms·
This is the type of innovation we exchange for a sense of absolute security in having highly-vetted decade-long bio R&D and extensive backlogs at the FDA for ap
by dmix 10y ago
This is the type of innovation we exchange for a sense of absolute security in having highly-vetted decade-long bio R&D and extensive backlogs at the FDA for approvals to sell products on the market. It's go big or go home because the regulatory risk/timeline is so extensive.
Most of these things die quietly or never get started so we never really see the true costs of what it takes to push the pharma world forward. It likely has a big effect on reinforcing existing monopolies as they are the only ones who can play that game (and pharma has been dominated by the same six companies since the 1800s). Usually R&D happens via a single trajectory which is either expensive internal labs at these companies or via anointed universities. There is very little variation on the source.
There's rarely an investment market between small scale seed stage and high growth phase. Which is where these bio R&D projects die.
Maybe there is an opportunity for a YC-style org to disrupt here. But I doubt it given the requirements to get to market.
- lend000 10y ago> sense of absolute security Well said -- the keyword is "sense" of security.
- barrkel 10y agoThere's also the small matter of profiting from desperation with unproven remedies that do unknown, possibly permanent damage. There are good reasons and historical precedent for strong medicine safety regulations; it's not just bureaucracy.
- lend000 10y agoPreventing fraud is one thing. Holding fraudsters responsible is a thing. However, barring access outright to (properly labeled) experimental medicine is completely different, and that's what the FDA does (as well as enforce a bunch of monopolies).
- WalterBright 10y agoThis was covered in Sam Peltzman's "Regulation of Pharmaceutical Innovation" book, where he goes over the statistics before/after the 1962 FDA Amendments. Statistically, the percentage of drugs that later prove to be ineffective or damaging is no different, just the aggregate amount of new drugs, good and bad, is way less.
- charlieflowers 10y agoAre there other nations which have less demanding requirements, but still decent vetting? Why can't these kinds of ideas go there?
- bdamm 10y agoMy scientist friends tell me China is paying well, making funding available, and has a lower go-to-market burden. Innovation appears to be literally moving to China as talent is being drained away from the US & Europe.
- Gtifn 10y agoJust for biotech?
- meric 10y agoI'd count commodity electronics in there.
- blackbagboys 10y agoThey have a lower go-to-market burden because the regulators don't much mind if you literally fabricate long-term clinical trial results out of whole cloth. The only innovation occurring is in the field of separating fools from their money.
- sirtaj 10y agoI've seen how clinical trials take place here in India and yes, it's not always pretty. There are plenty of people who mean well and do good work, but the pressure to reduce cost invariably leads to shortcuts.
- hprotagonist 10y agoRussia, too. http://www.cardiobrief.org/2017/04/26/serious-questions-raised-about-integrity-of-international-trials/ http://www.cardiobrief.org/2017/04/26/serious-questions-rais...
- deleted 10y ago[deleted]
- Animats 10y agoNo, this hasn't gotten anywhere near human testing yet. The FDA isn't involved.
- TaylorAlexander 10y agoFDA rules increase barriers to entry to the market, resulting in fewer companies (especially fewer smaller companies) who would be interested in funding such a project.
- johncolanduoni 10y agoIf you got DRACO to work in animals, there isn't a pharmaceutical company (or VC) on the planet that wouldn't buy you a small island just to get you to the table. This is probably the worst example you could choose for trying to demonstrate FDA regulations chilling development next to CRISPR. It's the in vitro -> in vivo part that they're anxious about wasting money on, not the FDA process.
- dmix 10y agoObviously it will be in the future, which deters any small scale seed investment...
- gozur88 10y agoBut FDA rules loom large in every decision in medicine. Avenues of research that are going to produce results that will be difficult to bring to market are likely to be abandoned even before the government is involved by law. That's not necessarily a bad thing.
- Fomite 10y agoThis is nowhere near the "This is getting tangled up in the FDA" phase. Funding speculative science is hard, and expensive, and this is the type of innovation we exchange for wanting more certain returns on investment, and nothing more than that.